The Phillip A. Sharp Innovation in Collaboration Awards Fund Colorectal, Ewing Sarcoma, Pancreatic, Lung and Pediatric Cancer Research
LOS ANGELES – July 29, 2020 — Stand Up To Cancer® announced today five new awards that will cut across institutional and national lines to foster collaborative research and explore new paths to improve cancer treatment. The projects will receive a combined total of $1.1 million in funding to address some of the most pressing questions associated with colorectal, Ewing sarcoma, pancreatic, lung and pediatric cancers.
Named for Nobel laureate Phillip A. Sharp, PhD, chairperson of Stand Up To Cancer’s Scientific Advisory Committee, the Phillip A. Sharp Innovation in Collaboration Awards focus on bringing new perspectives together to benefit cancer research. Sharp is an Institute professor at David H. Koch Institute for Integrative Cancer Research at Massachusetts Institute of Technology.
“What sets Stand Up To Cancer apart is its ability to break down historically restrictive silos that cancer researchers have typically worked in,” said Sharp. “These grants allow us to further emphasize the importance of collaboration among researchers across different institutions and specialties so that we can bring together the resources and brainpower needed to address some of the biggest challenges we face in cancer research and treatment today.”
The Sharp Awards are unique in their collaborative format, but also in the simple and quick selection process. The grants were selected at the annual Stand Up To Cancer Scientific Summit in January 2020 and were based on a 250-word outline of the idea that was reviewed by a board of experts at the summit. Each winning proposal submits a more detailed application before the grant is confirmed. Leaders of each team must be from different existing Stand Up To Cancer research teams. The program, now in its seventh year, encourages the inclusion of early-career investigators.
“The unique nature of the Sharp Awards allows for the extraordinary talent across the SU2C community to come together from different teams and individual grants to tackle some of the toughest new questions facing cancer research,” said William G. Nelson, MD, PhD, vice chair of the Stand Up To Cancer Scientific Advisory Committee and director of the Sidney Kimmel Comprehensive Cancer Center Johns Hopkins. “These new grants will help to build upon existing research, while creating the opportunity for researchers to work together on new and innovative projects.”
The American Association for Cancer Research, Stand Up To Cancer’s scientific partner, will support the administration of these projects receiving funding for the 2020 Sharp Awards, including:
Special awards this year were funded by the Emily Whitehead Foundation, the Kate McGarrigle Fund, and the Steve Golin Prize.
The Emily Whitehead Foundation is named after the first pediatric patient to receive CAR-T therapy for leukemia. These special awards focus specifically on addressing various therapeutic areas in pediatric cancer research. “We are honored to continue our collaboration with SU2C to fund these researchers focused on furthering pediatric cancer immunotherapy treatments,” said Tom Whitehead, co-founder of the Emily Whitehead Foundation. “Collaborative research is essential to developing new, successful treatments. Our hope is that by funding these research grants we will be able to give more kids the chance to survive their cancer and lead happy, healthy lives.”
The SU2C Kate McGarrigle Fund is a collaboration of Stand Up To Cancer and singers Rufus Wainwright and Martha Wainwright that raises much-needed funds for sarcoma research and provides music resources to cancer patients and survivors with a passion for music through the Music As Healing program. Kate McGarrigle, Canadian singer, songwriter, mother of Rufus Wainwright and Martha Wainwright, died of sarcoma in 2010.
The Steve Golin Fund accelerates research in Ewing sarcoma, in memory of Steve Golin, the American film producer who died of Ewing sarcoma in 2019. Ewing sarcoma is a rare bone and soft tissue cancer predominantly found in children.
About Stand Up To Cancer
Stand Up To Cancer® (SU2C) raises funds to accelerate the pace of research to get new therapies to patients quickly and save lives now. SU2C, a division of the Entertainment Industry Foundation, a 501(c)(3) charitable organization, was established in 2008 by media and entertainment leaders who utilize these communities’ resources to engage the public in supporting a new, collaborative model of cancer research, to increase awareness about cancer prevention, and to highlight progress being made in the fight against the disease. As of June 2020, more than 1,600 scientists representing more than 180 institutions are involved in SU2C-funded research projects.
Under the direction of our Scientific Advisory Committee, led by Nobel laureate Phillip A. Sharp, Ph.D., SU2C operates rigorous competitive review processes to identify the best research proposals to recommend for funding, oversee grants administration, and ensure collaboration across research programs.
Current members of the SU2C Council of Founders and Advisors (CFA) include Katie Couric, Sherry Lansing, Kathleen Lobb, Lisa Paulsen, Rusty Robertson, Sue Schwartz, Pamela Oas Williams, and Ellen Ziffren. The late Laura Ziskin and the late Noreen Fraser are also co-founders. Sung Poblete, Ph.D., R.N., serves as SU2C’s CEO. For more information, visit StandUpToCancer.org.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes 46,000 laboratory, translational, and clinical researchers; population scientists; other health care professionals; and patient advocates residing in 127 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis, and treatment of cancer by annually convening more than 30 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 22,500 attendees. In addition, the AACR publishes nine prestigious, peer-reviewed scientific journals and a magazine for cancer survivors, patients, and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the Scientific Partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration, and scientific oversight of team science and individual investigator grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and other policymakers about the value of cancer research and related biomedical science in saving lives from cancer. For more information about the AACR, visit www.AACR.org.
# # #
Stand Up To Cancer